Wu et al. (2021) further revealed the anti-prostate cancer mechanism of melatonin: Melatonin inhibits O-GlcNAcylation of cyclin-dependent kinase 5 (CDK5) at Thr246, thus promoting its degradation, and inhibiting the tumor-promoting effect of CDK5 on BC cells. This evidence concerns the gene CDK5 and prostate carcinoma.